Fund Holdings — Lynx1 Capital Management LP

Total Portfolio Value:
$279.23M
Total Bought:
$124.15M
Total Sold:
$18.23M
Net Transaction:
+$105.91M
Notable People:
Weston Agnew Nichols
Securities
▲▼
SharesValue
Q4 2024
▲▼
Q1 2025
▲▼
Change
▲▼
Q4 2024
▲▼
Q1 2025
▲▼
Weight (%)
▲▼
Change
▲▼
GH Research PLC(GHRS)4,858,9946,443,940+1,584,946$34.01M$71.08M25.45%+$37.06M
Merus N V1,580,8411,568,841-12,000$66.47M$66.03M23.65%-$441.8K
Protagonist Therapeutics Inc0733,014+733,014$0$35.45M12.69%+$35.45M
Stoke Therapeutics, Inc.(STOK)5,187,1915,291,929+104,738$57.21M$35.19M12.60%-$22.02M
Cullinan Therapeutics, Inc.(CGEM)1,257,7953,215,722+1,957,927$15.32M$24.34M8.72%+$9.02M
Allogene Therapeutics Inc10,874,72311,057,009+182,286$23.16M$16.14M5.78%-$7.02M
C4 Therapeutics, Inc.(CCCC)6,852,7447,098,133+245,389$24.67M$11.36M4.07%-$13.31M
TScan Therapeutics, Inc.(TCRX)5,357,3475,357,3470$16.29M$7.39M2.65%-$8.89M
Precision BioSciences, Inc.(DTIL)766,051766,0510$2.92M$3.65M1.31%+$735.4K
iBio, Inc.CON NEW(IBIO)862,279862,2790$2.11M$3.47M1.24%+$1.35M
Passage Bio, Inc.(PASG)9,256,9539,256,9530$5.25M$3.27M1.17%-$1.98M
Upstream Bio, Inc.(UPB)240,042219,247-20,795$3.95M$1.34M0.48%-$2.60M
Neuphoria Therapeutics Inc45,80645,8060$157.1K$263.8K0.09%+$106.7K
Design Therapeutics, Inc.(DSGN)065,954+65,954$0$254.6K0.09%+$254.6K
Allakos Inc3,628,1440-3,628,144$4.39M$0—-$4.39M
Caribou Biosciences, Inc.(CRBU)680,1890-680,189$1.08M$0—-$1.08M
Centessa Pharmaceuticals PlcADS17,4000-17,400$291.4K$0—-$291.4K
Keros Therapeutics, Inc.(KROS)544,0010-544,001$8.61M$0—-$8.61M
Repare Therapeutics Inc79,1760-79,176$103.7K$0—-$103.7K
Vor Biopharma Inc.(VOR)637,2180-637,218$707.3K$0—-$707.3K
Page 1 of 1
Lynx1 Capital Management LP — 13F Holdings — Q1 2025 | TickerTrail